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S1 Table. Brain  and Plasma concentrations of TC299423 measured by 
[125I]epibatidine displacement 
Brain measurements 
Time, min Ki, pM [TC299423] in 
assay, nM 
[TC299423] in brain, 
pmol/mga 
Control 23 ± 2.3 0 0 
5 27 ± 2.5 2.2 ± 1.1 45 ± 25 
10 31 ± 1.7 4.4 ± 0.9 88 ± 18 
20 29 ± 0.4 3.7 ± 0.2 73 ± 4.0 
 
Blood measurements 
Time, min Vol serum for 
IC50, µL 
[TC299423] 
nM 
 
5 42 ± 9.7 250 ± 50  
10 28 ± 5.5 370 ± 70  
20 89 ± 18 120 ± 30  
Data are expressed as mean ± SEM 
a, Data are pmol TC299423 / mg of brain tissue 
   11 
3 | P a g e  
 
S2 Table. In vitro metabolism of TC299423, compared with varenicline. 
 Human 
microsomes 
Rat microsomes Turnover by human cytochrome P450 isoforms  
 Clearancea T1/2b Clearancea T1/2b CYP1A2c CYP2C9 c CYP2C19 c CYP2D6 c CYP3A4 c Human 
FMO3 c 
Varenicline 39 43 233 10 7 0 0 39 50  
TC299423 5 285 18 79 3 8 4 42 7 17 
The assay mixtures (final incubation volume of 125 μL) in 0.255 M phosphate buffer with 0.575% (w/v) KCl (pH 
7.4) contained PiB (1.0 μM), 2.0 mM nicotinamide-adenine dinucleotide phosphate (reduced form) (NADPH), 
and a recombinantly expressed cytochrome P450 enzyme preparation (1A2, 2C9, 2C19, 2D6, 3A4, and FMO3) 
at 100 pmol/mL. After a 10 min preincubation at 37 oC, the reaction was initiated by addition of 2.0 mM NADPH 
and incubated for 60 min. The reactions were terminated by the addition of two volumes of DMSO. Samples 
were subsequently centrifuged at 4,000 rpm for 10 min. From the resulting supernatant, 10 μL was analyzed 
by liquid chromatography/tandem mass spectrometry (LC-MS/MS). Control experiments were performed by 
substituting the active enzyme preparation by cell preparations containing no recombinant human CYP. 
a, Data for clearance are given as μL/min/mg protein. 
b, Unit for T1/2 is min. 
c, Data for cytochrome P450 turnover and for human flavin-containing monooxygenase 3 (FMO3) are given as 
percent decline over 60 min. 
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S3 Table.  Competition binding on 70 target proteins tested at a concentration of 1 µM TC299423 
Inhibition Assay Name Radioligand/Substrate Hit 
12.86% Adenosine Transporter (h) [3H]-NBTI FALSE 
7.85% Adenosine, A1 [3H]CPX FALSE 
1.51% Adenosine, A2A (h) [3H]CGS 21680 FALSE 
-0.05% Adrenergic, Alpha 1A [3H]-7-MeOxy-Prazosin FALSE 
-8.31% Adrenergic, Alpha 1B [3H]-7-MeOxy-Prazosin FALSE 
6.75% Adrenergic, Alpha 2A (h) [3H]MK-912 FALSE 
-14.09% Adrenergic, Alpha 2B [3H]MK-912 FALSE 
6.28% Adrenergic, Alpha 2C (h) [3H]MK-912 FALSE 
11.21% Adrenergic, Beta 1 (h) [125I] (-) Iodocyanopindolol FALSE 
-8.25% Adrenergic, Beta 2 (h) [125]I-Iodo-cyanopindolol FALSE 
-5.87% Dopamine Transporter [3H]WIN 35,428 FALSE 
-2.94% Dopamine, D1 (h) [3H]-SCH23390 FALSE 
-21.17% Dopamine, D2s (h) [3H]-Raclopride FALSE 
-16.93% Dopamine, D3 [3H]7-OH-DPAT FALSE 
-2.44% Dopamine, D4.4 (h) [3H]-YM-09151-2 FALSE 
-2.66% GABA A, Agonist Site [3H]GABA FALSE 
11.84% GABA A, BDZ, alpha 1 site [3H]Flunitrazepam FALSE 
-2.43% GABA-B [3H]CGP 54626A FALSE 
-1.26% Glutamate, AMPA Site (Ionotropic) [3H]AMPA FALSE 
-6.93% Glutamate, Kainate Site (Ionotropic) [3H]Kainic acid FALSE 
5.46% Glutamate, MK-801 Site (Ionotropic) [3H]MK-801 FALSE 
5.51% Glutamate, NMDA Agonist Site (Ionotropic) [3H]CGP 39653 FALSE 
7.71% Glutamate, NMDA, Phencyclidine Site (Ionotropic) [3H]TCP FALSE 
4.34% Glutamate,NMDA,Glycine (Stry-insens Site) (Ionot [3H]-MDL-105,519 FALSE 
-7.63% Glycine, Strychnine-sensitive [3H]Strychnine FALSE 
15.56% Histamine, H1 [3H]Pyrilamine FALSE 
6.50% Histamine, H2 [125I]-Aminopotentidine FALSE 
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5.85% Histamine, H3 [3H]N-a-MeHistamine FALSE 
-11.73% Muscarinic, M1 (hr) [3H]Scopolamine, N-Methyl FALSE 
-3.18% Muscarinic, M2 (h) [3H]Scopolamine, N-Methyl FALSE 
-4.77% Muscarinic, M3 (h) [3H]Scopolamine, N-Methyl FALSE 
-6.69% Muscarinic, M4 (h) [3H]Scopolamine, N-Methyl FALSE 
2.24% Muscarinic, M5 (h) [3H]Scopolamine, N-Methyl FALSE 
93.33% Nicotinic, Neuronal (α-BnTx insensitive) [3H]Epibatidine TRUE 
23.72% Norepinephrine Transporter [3H]Nisoxetine FALSE 
-2.12% Opioid, Delta 2 (h) [3H]-Naltrindole FALSE 
-6.43% Opioid, Mu (h) [3H]-Diprenorphine FALSE 
7.03% Serotonin Transporter [3H]Citalopram, N-Methyl FALSE 
17.60% Serotonin, 5HT1A (h) [3H]-8-OH-DPAT FALSE 
9.99% Serotonin, 5HT1D [3H]5-CT FALSE 
12.43% Serotonin, 5HT2A [3H]Ketanserin FALSE 
-2.21% Serotonin, 5HT2C [3H]Mesulergine FALSE 
7.50% Serotonin, 5HT3 [3H]GR 65630 FALSE 
-16.64% Serotonin, 5HT4 [3H]GR 113808 FALSE 
1.24% Serotonin, 5HT5A (h) [3H]-LSD FALSE 
8.87% Serotonin, 5HT6 (h) [3H]-LSD FALSE 
-2.10% Serotonin, 5HT7 (h) [3H]LSD FALSE 
-0.52% Sigma 1 [3H]-(+)-Pentazocine FALSE 
-0.65% Sigma 2 [3H]-DTG FALSE 
-3.91% Calcium Channel, Type L (Dihydropyridine Site) [3H]Nitrendipine FALSE 
-0.60% Calcium Channel, Type N [125I]-Conotoxin GVIA FALSE 
6.83% GABA, Chloride, TBOB Site [3H]TBOB FALSE 
52.12% Potassium Channel, ATP-Sensitive [3H]Glibenclamide TRUE 
-2.57% Potassium Channel, Ca2+ Act., VI [125I]Apamin FALSE 
14.46% Potassium Channel, I[Kr] (hERG) (h) [3H]Astemizole FALSE 
6.91% Sodium, Site 2 [3H]Batrachotoxin A 20-a-Benzo FALSE 
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-10.86% Nitric Oxide, NOS (Neuronal-Binding) [3H]NOARG FALSE 
29.86% Leukotriene, LTB4 (BLT) [3H]LTB4 FALSE 
-8.26% Leukotriene, LTD4 (CysLT1) [3H]LTD4 FALSE 
3.14% Thromboxane A2 (h) [SQ 29,548] 3H SQ 29,548 FALSE 
24.85% Angiotensin II, AT1 (h) [125I]-(Sar1-Ile8) Angiotensin FALSE 
32.29% Bradykinin, BK2 [3H]Bradykinin FALSE 
8.93% Endothelin, ET-A (h) [125I] Endothelin-1 FALSE 
2.10% Neurokinin, NK1 [3H]Substance P FALSE 
2.16% Neuropeptide, NPY2 (h) [125I]-PYY FALSE 
21.55% Esterase, Acetylcholine Acetylthiocholine FALSE 
e12.00% Phosphodiesterase, PDE4A1A (h) Fluorescent cyclic AMP FALSE 
-3.00% Phosphodiesterase, PDE5A1 (h) Fluorescent cyclic GMP FALSE 
-5.00% Kinase, Protein, PKA (h) Fluorescein-labeled peptide FALSE 
-1.00% Kinase, Protein, PKCa (h) Fluorescein-labeled peptide FALSE 
 
TC299423 inhibited >50% of the reference radioligand for two sites: Neuronal nAChRs and ATP-sensitive 
potassium channels. 1µM TC299423 inhibited 93.33% of the [3H]-epibatidine binding at nAChRs and 52.12% 
of the [3H]-Glibenclamide binding at the ATP-sensitive potassium channels. 
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S1 Figure. Functional assays for measuring TC299423 agonist activity at various nAChRs. All points are 17 
mean ± SEM. A) Closed symbols show α-CtxMII-resistant [3H]-dopamine release and α-CtxMII-sensitive [3H]-18 
dopamine release from WT and α5KO striatal synaptosomes. Open symbols show [3H]-dopamine release 19 
evoked by 10 µM nicotine for the matching closed symbols. B) Measurement of functional α3β4*-nAChR by 20 
[3H]-ACh release from β2KO IPN synaptosomes. Curve fit EC50 and efficacy values for (A) and (B) are shown 21 
in Table 1 (see Results). C) Activity of TC299423 on α4β2* measured by high-sensitivity 86Rb+ efflux from WT 22 
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and α5KO thalamic synaptosomes. 2 µM DHβE was used to isolate the high-sensitivity and low-sensitivity 23 
responses. D) Activity of TC299423 on α4β2* measured by high-sensitivity 86Rb+ efflux from WT and α5KO 24 
cortical synaptosomes. As in C, 2 µM DHβE was used to distinguish between high-sensitivity and low-25 
sensitivity nAChRs. Calculated EC50 and efficacy values for (C) and (D) are presented in Table 2 (see Results). 26 
 27 
